pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
◐
Sign In
Subscribe
🐶
home
jobs
news
search
AMGEN · news · pharmadog
← back to AMGEN
News mentioning AMGEN
112
stories
18d
Amgen says hackers stole patient data in cloud breach
endpoints
21d
Replimune’s twice-rejected melanoma drug prevails in FDA adcomm
fiercebiotech
21d
Chutes & Ladders—Legend CEO departs without successor in place
fiercebiotech
22d
STAT+: Rising oil prices can boost the cost of some medicines. One expert says it’s time to lower reliance on fossil fuels
stat
22d
STAT+: Pharmalittle: We’re reading about an FDA panel nixing a Duchenne drug, FTC suing Hims & Hers, and more
stat
23d
STAT+: Pharmalittle: We’re reading about a fugitive who became a biotech exec, a hospital suing Lilly, and more
stat
23d
7 companies hiring in New York now
biospace
23d
Capricor and Replimune prep for FDA adcomms, Q2 earnings roll on, Sarepta’s new leader, more
biospace
24d
STAT+: Pharmalittle: We’re reading about FDA views on a Duchenne drug, GSK cost savings, and more
stat
24d
Guardant Health taps Patrick Dempsey for emotional colorectal cancer awareness video
fiercebiotech
24d
STAT+: HIV resurgence is feared as global funding to combat the disease falls 18%
stat
25d
Sarepta, in search of a turnaround, taps ex-AbbVie exec Severino as CEO
biopharma dive
25d
STAT+: Pharmalittle: We’re reading about a U.S. peptide panel’s votes, Amgen scuffling with the FDA, and more
stat
25d
InnoCare’s oral TYK2 inhibitor clears phase 3 psoriasis test
fiercebiotech
27d
Amgen shares new Tavneos analysis in effort to resolve FDA dispute
endpoints
28d
Amgen sheds around 40 staffers amid continuing struggles
fiercebiotech
28d
Sanofi halts development of troubled immune drug in eczema
biopharma dive
28d
Amgen deploys patients to defend troubled Tavneos in FDA hearing request
biospace
28d
Scribe records upsized $129M IPO to bankroll lipid-lowering genetic meds
fiercebiotech
29d
Lilly, with new data, to seek FDA approval of obesity drug retatrutide
biopharma dive
Jul 22, 26
6 companies hiring in Cambridge now
biospace
Jul 22, 26
Crystalys nets $130M more to push gout drug through late-stage tests
biopharma dive
Jul 22, 26
Q2 earnings underway, FDA’s CRL kerfuffle, IPOs full speed ahead in H2
biospace
Jul 21, 26
Indian generics maker Lupin seeds US spinout Kaveri with cash, clinical-phase cancer assets
fiercebiotech
Jul 20, 26
Scribe aims for $96M IPO to fund clinical push for lipid-lowering genetic meds
fiercebiotech
Jul 20, 26
How Kyverna rode CAR T’s autoimmune wave to the FDA’s door
biospace
Jul 19, 26
Latigo preps IPO to fund non-opioid pain drug rival to Vertex’s Journax
fiercebiotech
Jul 17, 26
Jasper finds new purpose in merger with Kira, while offloading Tavneos rival to Mirador
fiercebiotech
Jul 16, 26
Chutes & Ladders—Cue lines up new CMO and research head
fiercebiotech
Jul 16, 26
Merck wins first approval of a PCSK9 cholesterol pill
biopharma dive
← prev
page 2 of 4
next →
